News by subject: TRI

In this free webinar, learn about the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed...

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") , a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced the resubmission of the Company's Biologics...

ProJenX, a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other debilitating brain diseases, today announced that...

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, is pleased to announce its role at the 4th Annual Gene Therapy Comparability Summit taking place February 13-15, 2024, in...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today shared positive results from the Phase 1...

Flamingo Therapeutics ("Flamingo") today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with recurrent/metastatic head...

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that disease education and data from the Phase 2b study of rocatinlimab (AMG451/KHK4083), an investigational product being studied in patients with moderate-to-severe atopic dermatitis, will be...

The CHU Sainte-Justine Foundation invites media representatives to attend the Sainte-Justine Winter Triathlon, a Nordic challenge that each year brings together the business community around a single goal: to actively support CHU Sainte-Justine's...

Oncolytics Biotech® Inc. , a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab...

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber;...

GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024...

Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024. The conference will...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it has received clearance from the US Food and Drug...

Abbott today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for...

Heligenics, Inc., introduces a groundbreaking advancement in the discovery of new medicines. This cutting-edge research marks a pivotal moment in the field of biopharmaceuticals, in which High Content Screening, historically used for screening...

Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company to advance drugs for complex diseases, today announced the initiation of a clinical program in Colombia, starting with the translation of the widely-used Rett Syndrome...

Expert Systems Inc., a private company (ESI), announces the initiation of a first-in-human trial of TRX01 by their partner Trawsfynydd Therapeutics, a private company. Expert Systems deployed their accelerator platform to engineer this cutting-edge...

Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is...

?Keystone Lab, a dual-CAP accredited and CLIA certified lab based in Asheville, NC, has officially added tianeptine to its in-house urine clinical toxicology menu. Keystone provides clinical and forensic toxicology testing services throughout the...

FibroBiologics ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials encompassing 150+ patents issued and...

Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year. This grant, with Takeda contributing $500,000 of the $1,000,000 award,...

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming...

Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a condition associated with a high mortality rate...

TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP Participants treated with TPN-101 for the entire 48-week study in PSP showed a stabilization of their clinical symptoms...

PatenSee, developer of a fistula monitoring system for dialysis patients, has entered into an agreement with Fresenius Medical Care, a leading global provider of dialysis services....

In a study led by Prof. Dragu, Professor and Head of the Plastic Surgery Department at the University Medical Center in Dresden, Germany, the effectiveness of MatriDerm®, a dermal template manufactured by MedSkin Solutions Dr Suwelack, AG, has been...

Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with...

The Society of Neurolnterventional Surgery (SNIS) is acknowledging middle meningeal artery embolization (MMAE) as a beneficial adjunctive treatment for chronic subdural hematoma in light of new research. The minimally invasive MMAE procedure...

Trialbee, the global leader in technology-based patient recruitment for clinical trials, has introduced key features for the Insights Module in its Honey Platformtm to provide even greater visibility into recruitment ROI and projections....

GID BIO, Inc. completed enrollment for the first of two pivotal Phase III studies to investigate the use of your own stromal vascular fraction (SVF) cells to treat osteoarthritis of the knee. The clinical study involves a cellular therapeutic...

WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the upcoming launch of WCG ClinSpheretm, a revolutionary technology platform designed to enable an efficient and optimized clinical...

Trawsfynydd Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering antiviral treatments for respiratory viral diseases, today announced of a first-in-man clinical trial of the novel best-in-class COVID-19 treatment,...

Experts from NYU Langone Orthopedics will present their latest clinical findings and research discoveries at the American Academy of Orthopaedic Surgeons' (AAOS) 2024 Annual Meeting, February 12-16, in San Francisco....

Nasal powder formulations of epinephrine demonstrated superior stability and comparable plasma exposure to EpiPens according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting. "Nasal powder...

Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with...

Ritual, the traceable health and wellness brand working to raise the standard in the supplement industry, today announced the completion of its clinical trial on HyaCeratm, the brand's daily skin support supplement. The clinical study conducted in...

BIOTRONIK, a leader in implantable medical device technology, announced today they will solely supply their proprietary DX models for new single-chamber ICD implants moving forward. The move is being made in response to overwhelming recent clinical...

Kintara Therapeutics, Inc. ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the initiation of a REM-001 15-patient clinical trial (NCT05374915) in cutaneous...

CymaBay Therapeutics, Inc. , a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA)...

VST Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from a recent large animal study performed by VST Bio and Yale University demonstrating that a single iv bolus of...

Advarra, the market leader in regulatory review solutions and clinical research technology for sites and sponsors, announces single sign-on technology for clinical trial sites to reduce friction, increase security and free time to focus on patients....

Anixa Biosciences, Inc. ("Anixa" or the "Company") , a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fourth patient in the ongoing Phase 1 clinical trial...

Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), has successfully completed a decentralized trial for the Sana Device. Sana has...

Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing...

uMotif ? one of the clinical research technology market's fastest-growing companies ? and MoCA Cognition, creators of the leading test for early cognitive impairment detection ? are collaborating to make it easier for sponsors and CROs to...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today...

Frozen shoulder, also known as adhesive capsulitis, is a condition characterized by pain and stiffness in the shoulder, resulting in difficulty of movement in the shoulder. It affects 2-5% of the population, typically those between 40 and 60 years of...

InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology. Dr....

Orexo AB (publ.), (STO: ORX) , today announces the company agreed with Swedish Orphan Biovitrum AB...

Global biotechnology leader CSL today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular...